Variation in GYS1 Interacts with Exercise and Gender to Predict Cardiovascular Mortality

Jenny Fredriksson,1, Dragi Anevski,1,2, Peter Almgren,1, Marketa Sjögren,1, Valeriya Lyssenko,1, Joyce Carlson,1, Bo Isomaa,3, Marja-Riitta Taskinen,4, Leif Groop1,4,5, Marju Orho-Melander,1* for the Botnia Study Group

1 Department of Clinical Sciences in Malmö, Clinical Research Centre, Lund University, Malmö, Sweden, 2 Department of Mathematical Sciences, Chalmers University of Technology, Göteborg, Sweden, 3 Folkhalsan Genetic Institute, Folkhalsan Research Center, Biomedicum, Helsinki and Malmö Municipal Health Care Center and Hospital, Jakobstad, Finland, 4 Department of Medicine, Helsinki University Central Hospital, University of Helsinki, Finland, 5 Research Program of Molecular Medicine, University of Helsinki, Helsinki, Finland

Background. The muscle glycogen synthase gene (GYS1) has been associated with type 2 diabetes (T2D), the metabolic syndrome (MetS), male myocardial infarction and a defective increase in muscle glycogen synthase protein in response to exercise. We addressed the questions whether polymorphism in GYS1 can predict cardiovascular (CV) mortality in a high-risk population, if this risk is influenced by gender or physical activity, and if the association is independent of genetic variation in nearby apolipoprotein E gene (APOE). Methodology/Principal Findings. Polymorphisms in GYS1 (XbaIC>T) and APOE (−219G>T, e2/e3/e4) were genotyped in 4,654 subjects participating in the Botnia T2D-family study and followed for a median of eight years. Mortality analyses were performed using Cox proportional-hazards regression. During the follow-up period, 749 individuals died, 409 due to CV causes. In males the GYS1 XbaI T-allele (hazard ratio (HR) 1.9 [1.2–2.9]), T2D (2.5 [1.7–3.8]), earlier CV events (1.7 [1.2–2.5]), physical inactivity (1.9 [1.2–2.9]) and smoking (1.5 [1.0–2.3]) predicted CV mortality. The GYS1 XbaI T-allele predicted CV mortality particularly in physically active males (HR 1.7 [1.3–2.0]). Association of GYS1 with CV mortality was independent of APOE (219TT/e4), which by its own exerted an effect on CV mortality risk in females (2.9 [1.9–4.4]). Other independent predictors of CV mortality in females were fasting plasma glucose (1.2 [1.1–1.2]), high body mass index (BMI) (1.0 [1.0–1.1]), hypertension (1.9 [1.2–3.1]), earlier CV events (1.9 [1.3–2.8]) and physical inactivity (1.9 [1.2–2.8]). Conclusions/Significance. Polymorphisms in GYS1 and APOE predict CV mortality in T2D families in a gender-specific fashion and independently of each other. Physical exercise seems to unmask the effect associated with the GYS1 polymorphism, rendering carriers of the variant allele less susceptible to the protective effect of exercise on the risk of CV death, which finding could be compatible with a previous demonstration of defective increase in the glycogen synthase protein in carriers of this polymorphism.

INTRODUCTION

Cardiovascular (CV) disease (CVD), including coronary heart disease (CHD) and stroke, is the leading cause of death and disability in the Western world [1] and is thought to result from a complex interaction between genetic and environmental factors. Such risk factors are age, male gender, smoking, hypertension, diabetes, dyslipidemia [2] and physical inactivity. The genetic constitution of an individual usually determines how the individual responds to these risk factors. Therefore, it is necessary not only to identify which genetic variants increase susceptibility to the disease but also which environmental risk factors act in concert with these genes. In addition, the cellular environment in men and woman can be very different given known differences in hormonal milieu and gene expression [3]. Therefore, it is reasonable to consider the possibility that gender specific gene-environment interactions could modify the penetrance and expression of the trait.

Muscle glycogen synthase is the key enzyme in the synthesis of glycogen in skeletal muscle. A polymorphism (XbaI) in intron 14 of the glycogen synthase gene (GYS1) has been associated with lower glycogen synthase activity, T2D, features of the metabolic syndrome (MetS) and with myocardial infarction in males [4–8] but association to T2D has not been consistently replicated in all studies [9,10]. Interestingly, electrical stimulation of skeletal muscle to mimic physical exercise increased the amount of glycogen synthase in carriers of wild-type C-allele but not in carriers of the T-allele. As a consequence, carriers of the T-allele may benefit less from physical exercise than carriers of the normal allele [11]. GFS1 is located on chromosome 19q13.3, a region that has in several linkage studies been linked to MetS and T2D associated phenotypes [12–17]. Further, the GYS1 locus was in the HERITAGE family study linked to glucose effectiveness in response to endurance exercise [18]. GYS1 is separated only by 4.1 million base pairs from the gene coding for apolipoprotein E (APOE), which constitutes three

Copyright: © 2007 Fredriksson et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported by grants from the Diabetes Program at Lund University (DPLU), the Foundation for Strategic Research through the National Network for Cardiovascular Research, the Swedish Medical Research Council, the Swedish Foundation for the Study of Diabetes, the Albert Pålhlsson’s Foundation, Malmö University Hospital Foundation, Crafoord Foundation, the Lundberg Foundation, the Novo Nordisk Foundation, the Swedish Heart and Lung Foundation, the Medical Faculty of Lund University and EKGGENESIS CT-2004-005272. The Botnia Study is principally supported by the Sigrid Juselius Foundation, the Academy of Finland, the Finnish Diabetes Research Foundation, the Folkhalsan Research Foundation, and the Viktor Olkkokki Foundation.

Competing Interests: The authors have declared that no competing interests exist.

* To whom correspondence should be addressed. E-mail: marju.orho-melander@med.lu.se

Citation: Fredriksson J, Anevski D, Almgren P, Sjögren M, Lyssenko V, et al (2007) Variation in GYS1 Interacts with Exercise and Gender to Predict Cardiovascular Mortality. PLoS ONE 2(3): e285. doi:10.1371/journal.pone.0000285
common genetic isoforms in plasma and is known to play an important role in lipid metabolism [19]. The APOE4 isofrom encoded by the e4 allele is associated with elevated serum total- and low density lipoprotein (LDL)-cholesterol concentrations [20,21] and with coronary heart disease (CHD) [22,23]. In addition, a -219 (G>T) polymorphism in the APOE promoter has in vitro been shown to decrease transcriptional activity of APOE [24] and has been reported to associate with severity of coronary artery disease [25] and increased risk for myocardial infarction [26].

Given the considerations above, we set out to test 1) whether the GYS1 polymorphism is associated with CV mortality in individuals from a large T2D family study from Finland, the Botnia Study. In particular, we were interested in putative gender differences as the GYS1 polymorphism has earlier been associated with myocardial infarction only in males, 2) whether physical exercise would act as an environmental factor interacting with the effect associated with the GYS1 polymorphism as this has earlier been shown to be associated with defect in stimulation of glycogen synthase protein levels after muscle stimulation, and 3) to test if our results with the GYS1 polymorphism are independent of the adjacent APOE. As the endpoint we used CV mortality after a median follow up period of 8 years.

METHODS

Study Population
The Botnia Study was initiated in 1990 and represents a large population-based family study in Finland and Sweden aiming at identification of genes increasing susceptibility to T2D, MetS and related disorders. Details of the study cohort, sampling strategy as well as anthropometric and metabolic measurements have been described in detail [27,28]. The study protocol was approved by the local ethics committees and an informed consent was obtained from each subject before participating in the study. The present study was restricted to the original Botnia cohort of 4654 subjects from 965 families (2142 males, 2512 females, age 58.2 ± 13.8 years) from Western Finland. At the baseline examination, a structured questionnaire was completed by specially trained nurses, covering information about diseases other than T2D (particularly hypertension, coronary heart disease, myocardial infarction and stroke) and data on smoking habits and physical activity during work and leisure time. Both previous and current smokers were recorded as smokers. Physical activity level during work was defined on a scale from 0 to 6 according to level of physical activity (0 coding for no work and 6 for highest level) while physical activity during leisure time was estimated by a scale from 1 to 3 (1 = almost no activity at all, 2 = sometimes, but not regular, 3 = regular physical activity). Information on work and leisure time physical activity was combined to obtain an estimate of total physical activity level and classified as: 1) no physical activity or low physical activity (work level of 0 to 2 in combination of leisure time level of 1); 2) normal to high physical activity (work activity level 0–2 in combination of leisure time activity of >1; or work activity level ≥3 in combination of any leisure time activity level). When division between high and normal physical activity was needed, normal physical activity was defined as work activity level ≥3 and leisure time of <3 and high physical activity was defined as leisure time activity of 3 in combination with any work activity level. Glucose tolerance, assessed by an oral glucose tolerance test, and MetS were defined according to current World Health Organization (WHO) criteria [29]. Insulin resistance was estimated as the Homeostasis Model Assessment index (HOMA_\text{IR} = \text{fasting serum insulin} \times \text{fasting plasma glucose}/22.5).

Total and CV mortality was assessed with median follow up time of 7.9 years and mortality data were obtained from central death-certificate registry in Finland. CV mortality was classified using the 9th revision of the International Classification of Diseases (CV diagnosis codes 390–459) before 1997 and the 10th revision (codes 100–199) thereafter. Causes of death were classified as 1) CV death (CHD, cerebrovascular disease (including both thrombotic stroke and cerebral haemorrhage) or other CV events (including pulmonary embolism, abdominal aortic aneurysm, hypertensive complications, general atherosclerosis and peripheral artery disease with gangrene) or 2) other causes of death (neoplasia, violent or other).

Genotyping
A total of 4654 subjects were genotyped for the XbaI polymorphism in intron 14 (rs8103451) of GYS1 and for the APOE isoforms encoded by amino acid substitutions at residues 112 (rs429358) and 138 (rs7412), for the –219G>T promoter polymorphism (rs405509). The XbaI polymorphism in GYS1 was genotyped using single base pair extension on AB3100 (Applied Biosystems) and the APOE polymorphisms were genotyped using allelic discrimination on AB7900 at the SWEGENE DNA genotyping Laboratory. Before any analyses were performed, the expected risk-genotypes for GYS1 and APOE were defined as CT or TT (GYS1 XbaI), e3e3 or e4e4 (APOE codon 112 and 158 polymorphisms) and TT (APOE –219 polymorphism), respectively. Risk-alleles were defined according to previous T2D and MetS association study results for GYS1 XbaI [4,7,8] and reports on APOE and risk of coronary disease [22,25,26]. To assure high quality of the produced genotypes, a random sample of 17.8% of all GYS1 XbaI genotypes were repeated using PCR and restriction fragment length polymorphism and the concordance rate was 99.9% [30].

Statistical Analysis
Allele- and genotype frequencies between groups were compared by the χ² test or by Fisher’s exact test whereas multiple regression was used to compare clinical variables between groups, adjusting for age, sex and BMI. Hardy-Weinberg equilibrium (HWE) was tested using exact test (http://ihg.gsf.de/cgi-bin/hw/hwa1.pl) with alpha level of <0.05 for rejection. For the survival analyses the data were treated as left truncated and right censored, meaning that age was the basic time variable. Survival curves were obtained with the Kaplan-Meier estimator, and nonparametric two-sample tests for genetic effects were performed with the log-rank test. Covariates from the baseline visit were used. Effects of genetic and clinical variables on survival time were analysed with uni- and multivariate Cox regression analyses, stratified for sex and using a robust variance estimate to adjust for within family dependence by treating each pedigree as an independent entity when calculating the variance. The univariate analyses were performed to obtain relevant set of variables for multivariate analyses, therefore these p-values were not corrected for multiple testing. The multivariate Cox models were obtained by stepwise forward inclusion of the covariates and statistical significance of the model was analysed using the Wald test. Individuals with missing data for any of the covariates were excluded from the analyses. Due to missing data on microalbuminuria (data missing for 35%) this variable was not included in the multivariate analysis. Multiple tests were performed within the study (2 genes with 3 polymorphic sites and subanalyses in males and females). Concerning the XbaI polymorphism in males subanalyses were also performed according to physical activity level (low or normal to high). We did not correct for the number of analysed genes and polymorphisms as this study was designed to test the hypothesis that the T-allele of the GYS1 XbaI polymorphism could be associated with CV mortality and as the APOE markers were
studied to test if the GYS1 results are independent of the adjacent APOE. For the gender-specific analyses and for the analyses in individuals with different physical activity levels we report both non-adjusted (p) and adjusted (pc) p-values. The gender-specific analyses were multiplied with a factor of 3 (3 groups; all, males, females) and the physical activity analyses with a factor of 6 (3 groups with either low or normal to high physical activity).

All statistical analyses were performed using Number Crunching Statistical Systems version 2004 (NCSS; Kaysville, Utah, USA) or R (www.r-project.org). Two sided p-values of less than 0.05 were considered statistically significant. Estimates of linkage disequilibrium were calculated using the Haploview program [31]. Power calculations were performed using the normal distributions for the coefficient estimates in the Cox regression model [32].

RESULTS

Clinical and metabolic risk factors for CV mortality

During a median follow-up time of 7.9 years, 749 of the 4654 individuals (16.1%) had died and of them 409 (54.6%) due to CV causes (Table 1). Total mortality was slightly higher among males than among females (17.4 vs. 15.0%, p = 0.029), while frequency of CV mortality did not significantly differ between males and females (9.2 vs. 8.4%, p = 0.32). Subjects who died of CV causes had lower high density lipoprotein (HDL) cholesterol levels compared to both living subjects (p<0.0001) and individuals who died of other than CV causes (p = 0.0009). They also had higher triglyceride levels (p<0.0001) and higher frequency of T2D (p<0.0001), MetS (p = 0.0002), hypertension (p = 0.015), microalbuminuria (p<0.0001), earlier CV events (<0.0001) and lower physical activity level than subjects who were alive. CV death was associated with higher BMI (p = 0.046), total cholesterol levels (p = 0.0037), frequency of T2D (p<0.0001) and earlier CV events (p<0.0001) than death of other causes (Table 1).

Male gender, abdominal obesity, dyslipidaemia, T2D, hypertension, microalbuminuria, earlier CV events, smoking and low physical activity level were significant predictors of CV mortality among all individuals in univariate Cox regression analyses (Table 2). Gender specific univariate analyses identified low HDL cholesterol, T2D, hypertension, microalbuminuria, earlier CV events and physical inactivity as significant risk factors in both genders. Smoking was a significant risk factor only among male subjects while abdominal obesity and elevated triglyceride levels were significant predictors of CV death only in females (Table 2).

In multivariate analyses T2D, elevated fasting insulin concentration, earlier CV events, low physical activity and smoking were significant risk factors for CV mortality in males (model 1 in Table 3). In females T2D, high fasting glucose concentration, hypertension, earlier CV events, and physical inactivity were significant risk factors for CV mortality (model 1 in Table 4). Due to lack of data for a large part (35%) of the study subjects, microalbuminuria was not included in the multivariate model.

Allelic association between the GYS1 and APOE polymorphisms

Genotype frequencies of the GYS1 XbaI polymorphisms and APOE in the study population were: GYS1 XbaI C/T (CC 88.0%, CT 11.5%, TT 0.6%), APOE 219G>T (GG 29.5%, GT 50.2%, TT 20.3%), and APOE e2/e3/e4 (e2e2 0.4%, e2e3 9.4%, e2e4 2.3%, e3e3 59.4%, e3e4 25.2%, e4e4 3.2%). The genotypes of all single nucleotide polymorphisms (SNPs) (APOE Cys112Arg, Arg158Cys, -219G>T and GYS1 XbaI) and the relative frequencies of α-alleles, were in Hardy Weinberg equilibrium in the whole study population. Neither the genotype frequencies nor their combinations differed between males and females. The APOE -219G>T and Arg158Cys as well as the Arg158Cys and Cys112Arg polymorphisms were in complete linkage disequilibrium (D’ = 1.0). The GYS1 XbaI polymorphism was not in linkage disequilibrium with any of the three APOE SNPs (r’ = 0.0, for all and D’ = 0.12, 0.07 and 0.16, for APOE-219G>T, Cys112Arg and Arg158Cys, respectively).

GYS1 XbaI as a genetic predictor for CV mortality

The frequency of the XbaI risk genotypes (CT or TT) did not significantly differ between patients who died of CV causes, other causes or survivors when all subjects were included in the analyses (13.3%, 10.5%, and 12.0%) (Table 5). However, in gender-specific analyses, males with CV death had more often the CT/TT geno-
**TABLE 2. CLINICAL AND GENETIC RISK FACTORS FOR CV MORTALITY**

|                       | ALL INDIVIDUALS | MALE SUBJECTS | FEMALE SUBJECTS |
|-----------------------|-----------------|---------------|-----------------|
|                       | HR [95% CI]     | p             | HR [95% CI]     | p             |
| Male sex              | 1.6 [1.3–1.9]   | <0.0001       | 1.0 [1.0–1.1]   | 0.14           | 1.0 [1.0–1.1] | 0.078 |
| BMI (kg/m²)           | 1.0 [1.0–1.0]   | 0.060         | 1.0 [1.0–1.1]   | 0.14           | 1.0 [1.0–1.2] | 0.88  |
| WH                    | 27.6 [7.9–96.5] | <0.0001       | 3.7 [0.2–73.1]  | 0.39           | 18.8 [3.2–111.4] | 0.0012 |
| Cholesterol (mmol/l)  | 1.0 [0.9–1.1]   | 0.52          | 1.0 [0.9–1.2]   | 0.76           | 1.0 [0.9–1.2] | 0.88  |
| HDL-cholesterol (mmol/l) | 3.1 [2.0–4.1]   | <0.0001       | 2.5 [1.3–4.8]   | 0.0049         | 2.7 [1.7–4.1] | <0.0001 |
| Triglycerides (mmol/l)| 1.1 [1.1–1.2]   | 0.0017        | 1.1 [1.0–1.2]   | 0.16           | 1.4 [1.2–1.5] | <0.0001 |
| Type 2 diabetes       | 3.2 [2.5–4.2]   | <0.0001       | 3.2 [2.3–4.6]   | <0.0001        | 3.2 [2.2–4.8] | <0.0001 |
| Metabolic syndrome    | 1.3 [1.0–1.5]   | 0.030         | 1.3 [1.0–1.7]   | 0.10           | 1.2 [0.9–1.6] | 0.25  |
| Hypertension          | 1.4 [1.1–1.7]   | 0.0046        | 1.4 [1.1–1.9]   | 0.021          | 1.4 [1.0–2.0] | 0.036 |
| Microalbuminuria      | 2.3 [1.6–3.3]   | <0.0001       | 2.1 [1.3–3.3]   | 0.0014         | 2.3 [1.4–4.1] | 0.0022 |
| Earlier CV events     | 2.5 [2.0–3.0]   | <0.0001       | 2.8 [2.0–3.7]   | <0.0001        | 2.1 [1.6–2.8] | <0.0001 |
| Smoking               | 1.7 [1.3–2.1]   | <0.0001       | 1.5 [1.1–2.1]   | 0.0075         | 1.1 [0.5–2.2] | 0.83  |
| Low physical activity | 2.6 [2.0–3.3]   | <0.0001       | 2.9 [2.1–4.0]   | <0.0001        | 2.6 [1.9–3.6] | <0.0001 |
| APOE E3/E4/E4/E4       | 1.1 [0.9–1.4]   | 0.31          | 0.9 [0.6–1.2]   | 0.43           | 1.4 [1.0–1.9] | 0.030 |
| APOE –219 TT          | 1.1 [0.9–1.4]   | 0.32          | 0.8 [0.5–1.1]   | 0.19           | 1.5 [1.2–2.1] | 0.0082 |
| APOE risk genotype combination | 1.3 [1.0–1.8] | 0.064        | 0.6 [0.3–1.2]   | 0.14           | 2.3 [1.6–3.2] | <0.0001 |
| GYS1 Xbal CT/TT       | 1.2 [0.9–1.6]   | 0.24          | 1.8 [1.2–2.6]   | 0.0016         | 0.7 [0.4–1.2] | 0.18  |

Univariate Cox proportional-hazards analysis, performed with robust variance estimate to adjust for within family dependence. BMI; body mass index, WH; waist to hip ratio.
doi:10.1371/journal.pone.0000285.t002

**TABLE 3. MULTIVARIATE MODEL OF RISK FACTORS FOR CV MORTALITY IN MALES**

| RISK PHENO-/GENOTYPE | MODEL 1 CLINICAL VARIABLES | P | MODEL 2 CLINICAL AND GENETIC VARIABLES | P |
|----------------------|-----------------------------|---|--------------------------------------|---|
| GYS1 Xbal (T)        | 1.9 [1.2–2.9]               | 3.5e⁻³ * |                                      |   |
| T2D                  | 2.4 [1.6–3.7]               | 3.0e⁻⁵ | 2.5 [1.7–3.8]                        | 1.2e⁻⁵ |
| Fasting serum insulin| 1.0 [1.0–1.0]               | 3.5e⁻² |                                      |   |
| Earlier CV events    | 1.9 [1.4–2.7]               | 2.1e⁻⁴ | 1.7 [1.2–2.5]                        | 6.0e⁻³ |
| Low physical activity| 1.9 [1.3–2.8]               | 1.7e⁻³ | 1.9 [1.2–2.9]                        | 3.1e⁻³ |
| Smoking              | 1.6 [1.0–2.3]               | 3.4e⁻² | 1.5 [1.0–2.3]                        | 3.2e⁻² |
| P-value (model, Wald test) | 3.9e⁻¹⁴                   |   | 7.0e⁻¹¹                             |   |

**Does physical activity influence the effect associated with the genetic variation in GYS1 on CV mortality risk?**

CV mortality was significantly higher among individuals with low physical activity level compared to individuals with normal (29.9 vs. 7.1%, p<0.0001, corrected for sex and age) or high (29.9 vs. 5.7%, p<0.0001) physical activity level. The difference was not significant between groups reporting normal or high physical activity level (7.1 vs. 5.4%, p = 0.35) suggesting minimal or no protective effect above a normal level of physical activity on CV mortality risk. In a multivariate Cox regression analysis both physical activity (hazard ratio (HR) 3.2 [2.2–4.6], p<0.0001, p<0.0001) and the XbaI polymorphism (HR 2.6 [1.7–3.8], p<0.0001, p<0.0001) were strongly associated with CV mortality. While physical activity itself (normal or high) had a strong protective effect on CV mortality, this effect was attenuated in carriers of the CT/TT- genotypes of the Xbal polymorphism; physically active males with the CT/TT genotypes had a 2.7-times higher risk for CV mortality compared to CC-genotype carriers (HR 2.7 [1.8–4.1], p<0.0001, p<0.0001) (Figure 2).

**APOE polymorphisms as genetic predictors for CV mortality**

The frequency of the APOE ε2/ε3/ε4 risk genotypes (ε3ε4 or ε4ε4), the APOE –219 risk genotype (TT) or the risk genotype combination of APOEε and APOE –219 (–219TT/ε4) did not...
TABLE 4. MULTIVARIATE MODEL OF RISK FACTORS FOR CV MORTALITY IN FEMALES

| RISK PHENO-/GENOTYPE | MODEL 1 CLINICAL VARIABLES | P   | MODEL 2 CLINICAL AND GENETIC VARIABLES | P   |
|----------------------|----------------------------|------|----------------------------------------|------|
| APOE (E3E4/E4E4 and -219 TT) | 2.9 [1.9–4.4] | 5.4e-14 | 2.6e-6 * | 2.6e-6 * |
| T2D | 1.7 [1.0–2.9] | 1.0e-2 | 2.6e-2 |
| Fasting plasma glucose | 1.1 [1.1–1.2] | 3.9e-5 | 2.3e-10 |
| BMI | 1.0 [1.0–1.1] | 1.3e-1 | 2.2e-2 |
| Hypertension | 1.6 [1.1–2.4] | 2.9e-2 | 7.3e-3 |
| Earlier CV events | 1.6 [1.1–2.3] | 1.2e-2 | 5.9e-4 |
| Low physical activity | 2.1 [1.4–3.1] | 2.5e-4 | 4.9e-3 |
| P-value (model, Wald test) | 5.4e-14 | 1.0e-14 |

Multivariate Cox regression analysis using stepwise forward inclusion with robust variance estimates. Adjusted for age, sex and family correlations. * P_c = 7.8e-6
doi:10.1371/journal.pone.0000285.t004

Figure 1. CV mortality in males and females according to the GYS1 XbaI (A) and APOE -219TT/e4 (B) genotypes. Kaplan Meier survival curves illustrating a higher risk for CV mortality (HR 1.8 [1.2–2.6], p = 0.0016, p_c = 0.0096) in male carriers of the GYS1 XbaI CT/TT-genotypes and in female carriers of the APOE -219TT/e4 genotype combination (HR 2.3 [1.6–3.2], p<0.0001, p_c<0.0001).
doi:10.1371/journal.pone.0000285.g001
significantly differ between individuals who died of CV causes and other subjects (Table 5). However, females in the CV mortality group had more often the APOE–219 TT-genotype, in particular -219/TT/e4 compared to surviving females (26.9 vs. 19.8%, p = 0.019, p = 0.057 and 17.5 vs. 9.4%, p = 0.00048, p = 0.0014). No effect of the APOE variants was observed in males, this effect being restricted to females in whom both the APOE e4-allele, the –219 TT-genotype and their combination were significant predictors of CV mortality (Table 2 and Figure 1B), but not of non-CV mortality. When genetic and non-genetic factors were included in the analysis of risk of CV death, the APOE genotype, the –219 TT-genotype, in particular -219/TT/e4, was predicted to CV mortality only in carriers of the e3/e4 genotype (HR 2.3 [1.5–3.6], p = 0.00038, pc = 0.0023). The –219 polymorphism had no effect on cholesterol levels neither in female carriers nor non-carriers of the APOE e3/e4 genotypes, and predicted CV mortality only in carriers of the APOE e3/e4 genotypes (HR 2.3 [1.5–3.6], p = 0.00038, pc = 0.0023). In males, the APOE e3/e4/e4 genotypes affected total cholesterol in carriers (5.9±1.0 vs. 5.6±1.2 mmol/l, p = 0.031, for the e3/e4/e4 genotype vs. other genotypes, respectively) but not after correcting for multiple testing (p = 0.19) and not in non-carriers (5.7±1.0 vs. 5.6±1.1 mmol/l, p = 0.31) of the APOE –219 TT genotype. As in females, the APOE –219 TT genotype had no significant effect on cholesterol values neither in carriers nor non-carriers of the APOE e3/e4/e4 genotypes. In contrast to females, neither APOE e3/e4/e4 nor APOE –219 TT predicted CV mortality in males.

### Independancy between GYS1 and APOE as risk factors for CV mortality

To investigate whether the ‘at-risk’ genotypes of GYS1 and APOE contributed independently to the CV mortality risk, we performed Cox regression analyses by entering both genes into the equation. These analyses clearly indicated that the effect of GYS1 XbaI CT/TT in males [XbaI CT/TT: HR 1.9 [1.3–2.7], APOE –219/e4: HR 1.5 [0.9–2.5]], as well as the effect of APOE genotype combination in females [APOE –219/e4: HR 2.4 [1.7–3.6], GYS1 XbaI CT/TT: HR 1.3 [0.8–2.3]], were independent of each

#### Cholesterol levels and CV mortality according to APOE e3/e4/e4 and -219 TT genotypes

The APOE e3/e4/e4 and -219 TT genotypes (and their combination) were associated with increased total and LDL cholesterol levels in both males and females (after adjustment for age, T2D and BMI). Interestingly, although the APOE e3/e4/e4 variants had a statistically weaker effect on total cholesterol in female carriers (6.1±1.2 vs. 5.8±1.2 mmol/l, p = 0.014, p = 0.0084 for the e3/e4/e4 genotype vs. other genotypes) compared to non-carriers (6.1±1.2 vs. 5.8±1.1 mmol/l, p = 0.0001, p = 0.0006) of APOE –219 TT, they only predicted CV mortality in carriers of APOE –219 TT (HR 2.3 [1.3–4.2], p = 0.0059, pc = 0.035). The –219 polymorphism had no effect on cholesterol levels neither in female carriers nor non-carriers of the APOE e3/e4/e4, and predicted CV mortality only in carriers of the APOE e3/e4/e4 genotypes (HR 2.3 [1.5–3.6], p = 0.00038, pc = 0.0023).

To investigate whether the ‘at-risk’ genotypes of GYS1 and APOE contributed independently to the CV mortality risk, we performed Cox regression analyses by entering both genes into the equation. These analyses clearly indicated that the effect of GYS1 XbaI CT/TT in males [XbaI CT/TT: HR 1.9 [1.3–2.7], APOE –219/e4: HR 1.5 [0.9–2.5]], as well as the effect of APOE genotype combination in females [APOE –219/e4: HR 2.4 [1.7–3.6], GYS1 XbaI CT/TT: HR 1.3 [0.8–2.3]], were independent of each

### Independancy between GYS1 and APOE as risk factors for CV mortality

To investigate whether the ‘at-risk’ genotypes of GYS1 and APOE contributed independently to the CV mortality risk, we performed Cox regression analyses by entering both genes into the equation. These analyses clearly indicated that the effect of GYS1 XbaI CT/TT in males [XbaI CT/TT: HR 1.9 [1.3–2.7], APOE –219/e4: HR 1.5 [0.9–2.5]], as well as the effect of APOE genotype combination in females [APOE –219/e4: HR 2.4 [1.7–3.6], GYS1 XbaI CT/TT: HR 1.3 [0.8–2.3]], were independent of each

#### Table 5: Genotype distribution in subjects who died from CV causes and in subjects who are alive or died due to other causes

| GENE AND RISK GENOTYPE | CV DEATH | OTHER SUBJECTS |
|-----------------------|----------|----------------|
| All subjects (N=4654)| E3E4/E4E4| 27.2           |
| APOE –219/e4          |           | 28.6           |
| APOE –219             | TT       | 23.1           |
| APOE –219/e3/e4       |           | 20.1           |
| GYS1 XbaI CT/TT       |          | 12.8           |
| Males (N=2142)        | E3E4/E4E4| 10.2           |
| APOE –219/e4          |           | 7.7            |
| APOE –219             | TT       | 19.1           |
| APOE –219/e3/e4       |           | 20.8           |
| GYS1 XbaI CT/TT       |          | 19.1           |
| Females (N=2512)      | E3E4/E4E4| 29.1           |
| APOE –219/e4          |           | 11.2           |
| APOE –219             | TT       | 7.7            |
| APOE –219/e3/e4       |           | 11.8           |
| GYS1 XbaI CT/TT       |          | 17.5           |
| All subjects (N=4654)|           | 9.4            |
| APOE –219/e4          |           | 12.0           |

| CHOLESTEROL LEVELS AND CV MORTALITY ACCORDING TO APOE e3/e4/e4 AND -219 TT GENOTYPES |
|--------------------------------------|
| The APOE e3/e4/e4 and -219 TT genotypes (and their combination) were associated with increased total and LDL cholesterol levels in both males and females (after adjustment for age, T2D and BMI). Interestingly, although the APOE e3/e4/e4 variants had a statistically weaker effect on total cholesterol in female carriers (6.1±1.2 vs. 5.8±1.2 mmol/l, p = 0.014, p = 0.0084 for the e3/e4/e4 genotype vs. other genotypes) compared to non-carriers (6.1±1.2 vs. 5.8±1.1 mmol/l, p = 0.0001, p = 0.0006) of APOE –219 TT, they only predicted CV mortality in carriers of APOE –219 TT (HR 2.3 [1.3–4.2], p = 0.0059, pc = 0.035). The –219 polymorphism had no effect on cholesterol levels neither in female carriers nor non-carriers of the APOE e3/e4/e4, and predicted CV mortality only in carriers of the APOE e3/e4/e4 genotypes (HR 2.3 [1.5–3.6], p = 0.00038, pc = 0.0023). In males, the APOE e3/e4/e4 genotypes affected total cholesterol in carriers (5.9±1.0 vs. 5.6±1.2 mmol/l, p = 0.031, for the e3/e4/e4 genotype vs. other genotypes, respectively) but not after correcting for multiple testing (p = 0.19) and not in non-carriers (5.7±1.0 vs. 5.6±1.1 mmol/l, p = 0.31) of the APOE –219 TT genotype. As in females, the APOE –219 TT genotype had no significant effect on cholesterol values neither in carriers nor non-carriers of the APOE e3/e4/e4 genotypes. In contrast to females, neither APOE e3/e4/e4 nor APOE –219 TT predicted CV mortality in males. |

#### Figure 2: Interaction between the GYS1 XbaI polymorphism and physical activity (PA) in males. Kaplan Meier survival curves for males reporting normal to high physical activity (PA) level according to GYS1 XbaI genotype compared to males with low PA level. doi:10.1371/journal.pone.0000285.g002
other. To further assess the independence of the effects of the polymorphisms on CV mortality, the samples were stratified according to GYS1 and APOE genotypes. The XbaI T-allele was associated with CV mortality in males without the APOE risk genotype combination [HR 1.9 [1.3–2.0]] and the APOE risk-genotype combination was associated with cardiovascular mortality among female XbaI CC-carriers (HR 2.3 [1.6–3.5]).

**DISCUSSION**

The key findings of the present study were that 1) the XbaI polymorphism in GYS1 was associated with CV mortality in males; 2) although physical activity markedly reduces risk of CV death, this protective effect was attenuated in male carriers of the XbaI polymorphism; and 3) despite the fact that GYS1 is adjacent to APOE on chromosome 19q13, the effect of the GYS1 polymorphism on CV mortality is independent of the effect of APOE, which exerts a strong effect on CV mortality risk by its own. Interestingly, this risk seems to be restricted to females and cannot fully be explained by the effect of the APOE alleles on cholesterol levels.

Several studies performed in different ethnic populations have reported linkage to chromosome 19q13 for LDL-cholesterol- [33–37] or triglyceride levels [38], as well as for insulin resistance and T2D related phenotypes [12–17] but the underlying genetic variants have not been identified. In addition, glucose effectiveness in response to exercise training as well as significant sex specific differences in heritability models and sex interaction for HDL cholesterol have been mapped to the 19q13 region [18,41]. We therefore set out to study the contribution of two candidate genes in this region, GYS1 and APOE to CV mortality risk, focusing particularly on the role of putative interaction between GYS1 polymorphism and gender and/or physical activity level to affect the CV mortality rate.

The GYS1 XbaI polymorphism was significantly associated with increased risk for CV mortality in males, a result supported by our previous independent finding of an association between myocardial infarction and this particular polymorphism only in males in another study population [7].

As anticipated, a low physical activity level was a severe risk factor for CV mortality. The novel finding of our study was that the protective effect of physical exercise was attenuated in carriers of the XbaI polymorphism. This goes along with the hypothesis advanced by a Canadian study [11] that carriers of the risk T-allele have a defect in their ability to increase the glycogen synthase protein in response to neuromuscular electrical stimulation (as a proxy for physical exercise) [11]. An increase in glycogen synthase protein would promote glycogen formation which, in turn, could have a beneficial effect on exercise capacity. The downside of this message is that all individuals would not respond to physical exercise in the same way. The positive message is that the “non-responder” group is relatively small (frequency of CT/TT genotypes in the population is only 12%) and in 85% of the population exercise exerts a highly beneficial and protective effect on risk of CVD.

We have no apparent explanation for why the effect of the XbaI polymorphism was restricted to males. One potential explanation could be that women have less muscle mass and muscular strength than men, but also a tendency to metabolise fat rather than carbohydrate during exercise [42]. Moreover, women seem less vulnerable to exercise-induced sudden death [42]. A potential explanation could be that both exercise training and oestrogen increase Akt phosphorylation and glycogen synthase kinase-3 inactivation leading to increased glycogen synthase activity. Interestingly, markedly higher myocardial Akt nuclear activity has been reported in females than in males as well as in pre-compared to post-menopausal woman [43]. If this also applies to skeletal muscle it could provide a potential explanation for the observed gender-specific effect.

Our results are in agreement with the earlier results reporting either the APOE e4-allele or the APOE -219 TT-genotype as risk factors for CVD and/or mortality [22,23,25,26] but, interestingly, we could observe this effect only in females. Caution is, however, warranted in the interpretation of the gender-specific effects of APOE as the study included a large number of patients with T2D. It is known, that men with T2D have an excess mortality compared with women with T2D resulting in a relative increase in the frequency of female T2D patients with aging. It is therefore still possible that the APOE polymorphisms had an effect in male T2D resulting in premature death. A sub-analysis of men and women divided by the median of age did, however, not support such an explanation. Also, power is reduced when the analysis is restricted to gender. The power in a Cox regression analysis depends among other things on the accrual time during which patients are recruited, mean time to failure and the expected effect sizes [http://bioeas.mc.vanderbilt.edu/twiki/bin/view/Main/PowerSampleSize][44]. We used the standard Normal theory to calculate the power to detect a HR of a certain size [32]. Our study had a 73–96% power to detect hazard ratios of 1.5 for the analysed polymorphisms.

In conclusion, we demonstrate a protective effect of physical activity on CV mortality. However, in male subjects this effect was attenuated in carriers of the rare allele of the XbaI polymorphism in GYS1. This finding could be compatible with a previous demonstration of defective increase in the glycogen synthase protein in carriers of this polymorphism. We could exclude that the association between the GYS1 polymorphism and CV mortality was due to the adjacent APOE gene. Instead, we demonstrated that this gene exerted an increased risk of CV mortality in females. These findings re-emphasize the need to consider the effect of genetic variants in complex diseases in concert with their environmental triggers but also to evaluate whether females and males respond differently to genes and the environment.

**ACKNOWLEDGMENTS**

**Author Contributions**

Conceived and designed the experiments: LG MO JC BI. Performed the experiments: MS JF. Analyzed the data: PA DA MO JF. Contributed reagents/materials/analysis tools: LG VL MT MO MS JC BI. Wrote the paper: LG VL PA DA MT MO MS JC BI.

**REFERENCES**

1. Bethesda (2002) National Heart, Long and Blood Institute. NHLBI morbidity and mortality chartbook. www.nhlbi.nih.gov/resources/docs/hr-book.htm.
2. (1999) Summary of the second report of the National Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult treatment panel II). JAMA 269: 3015–3023.
3. Rinn JL, Snyder M (2005) Sexual dimorphism in mammalian gene expression. Trends Genet 21: 296–303.
4. Groop LC, Kankuri M, Schalin Jantti C, Ekstrand A, Nikula Ijas P, et al. (1993) Association between polymorphism of the glycogen synthase gene and non-insulin-dependent diabetes mellitus. N Engl J Med 328: 10–14.
11. St-Onge J, Joanisse DR, Simoneau JA (2001) The stimulation-induced increase in skeletal muscle glycogen synthase content is impaired in carriers of the glycogen synthase Xba1 polymorphism. Diabetes 50: 195–198.

12. Pratley RE, Thompson DB, Prochazka M, Baier L, Mojt D, et al. (1998) An autosomal genomic scan for loci linked to prediabetic phenotypes in Pima Indians. J Clin Invest 101: 1757–1764.

13. Watanabe RM, Ghosh S, Langefeld CD, Valle TT, Hauser ER, et al. (2000) Impact of the Xba1-polymorphism of the human muscle glycogen synthase gene on parameters of the insulin resistance syndrome in a Danish twin population. Diabet Med 17: 735–740.

14. Mori Y, Otabe S, Dina C, Yasuda K, Populaire C, et al. (2002) Genome-wide association analysis of the XbaI polymorphism in the muscle glycogen synthase gene. Diabetologia 45: 1138–1145.

15. Fenger M, Poulsen P, Beck-Nielsen H, Vissing A (2000) Toward a novel phenotypic marker for muscle glycogen synthase defect. J Appl Physiol 88: 2223–2230.

16. van Tilburg JH, Velgo G, Freque P (1993) Polymorphism of the glycogen synthase gene and non-insulin-dependent diabetes mellitus. N Engl J Med 328: 1568–1569.

17. Kadowaki T, Kadowaki H, Yazaki Y (1993) Polymorphism of the glycogen synthase gene and non-insulin-dependent diabetes mellitus. N Engl J Med 328: 1568–1569.

18. Rissanen J, Pihlajamaki J, Heikkinen S, Kekalainen P, Mykkänen L, et al. (1997) New variants in the glycogen synthase gene (Glyc1His, Mes1Val) in patients with NIDDM from eastern Finland. Diabetologia 40: 1313–1319.

19. St-Onge J, Joanisse DR, Simoneau JA (2001) The stimulation-induced increase in skeletal muscle glycogen synthase content is impaired in carriers of the glycogen synthase Xba1 polymorphism. Diabetes 50: 195–198.

20. Sing CF DJ (1985) Role of apolipoprotein E polymorphism in determining normal plasma lipid and lipoprotein variation. Am J Hum Genet 37: 268–285.

21. Mahley R (1988) Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 240: 622–630.

22. Fenger M, Poulsen P, Beck-Nielsen H, Vissing A (2000) Toward a novel phenotypic marker for muscle glycogen synthase defect. J Appl Physiol 88: 2223–2230.

23. van Tilburg JH, Velgo G, Freque P (1993) Polymorphism of the glycogen synthase gene and non-insulin-dependent diabetes mellitus. N Engl J Med 328: 1568–1569.

24. Rissanen J, Pihlajamaki J, Heikkinen S, Kekalainen P, Mykkänen L, et al. (1997) New variants in the glycogen synthase gene (Glyc1His, Mes1Val) in patients with NIDDM from eastern Finland. Diabetologia 40: 1313–1319.

25. Orho-Melander M, Almgren P, Kanninen T, Forsblom C, Groop LC (1999) A genome-wide scan of serum lipid levels in the Old Order Amish. Atherosclerosis 16: 1867–1874.

26. Lambert JC, Broussolle T, Defosse V, Evans A, Arviller D, et al. (2000) Independent association of an APOE gene promoter polymorphism with increased risk of myocardial infarction and decreased APOE plasma concentration.

27. Dupont W, Plummer Jr W. PS: Power and Sample Size Calculation.

28. Isomaa B, Almgren P, Tuomi T, Forsen B, Laht I, et al. (2001) Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24: 685–689.

29. Alberti KG, Zimmer PZ (1998) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation [see comments]. Diabet Med 15: 359–553.

30. Schalin-Jantti C, Niikula-Ijas P, Huang X, Lehto M, Knudsen P, et al. (1996) Polymorphism of the glycogen synthase gene in hypertensive and normotensive subjects. Hypertension 27: 67–71.

31. Barrett JC, Fry B, Maller J, Daly MJ (2005) Haplview: analysis and visualization of LD and haplotype maps. Bioinformatics 21: 26–263.

32. Casella G, Berger, R L (1990) Statistical Inference: Duxbury press; 360.

33. Beekman M, Heijmans BA, Mattheeuws JM, Peeters PLM, et al. (2005) Meta-analysis of four new genome scans for lipid parameters and analysis of diabetogenic alleles and risk of coronary disease. A meta-analysis. Arterioscler Thromb Vasc Biol 16: 1250–1255.

34. Song Y, Stampfer MJ, Liu S (2004) Meta-analysis: apolipoprotein E genotypes and risk for coronary heart disease. Ann Intern Med 141: 137–147.

35. Bosse Y, Chagnon YC, Despres JP, Rice T, Rao DC, et al. (2004) Genome-wide linkage scan reveals multiple susceptibility loci influencing lipid and lipoprotein levels in the Quebec Family Study. J Lipid Res 45: 419–426.

36. Adeyemo AA, Johnson T, Acheampong J, Oli J, Okafor G, et al. (2005) A genome wide quantitative trait linkage analysis for serum lipids in type 2 diabetes in an African population. Atherosclerosis 181: 389–397.

37. Heijmans BT, Beekman M, Putter H, Jansen L, van der Wijk HJ, et al. (2005) Meta-analysis of four new genome scans for lipid parameters and analysis of positional candidates in positive linkage regions. Eur J Hum Genet 13: 1143–1153.

38. Pollin TI, Huseh WC, Steiner RI, Sutker S, Shuldiner AR, Mitchell BD (2004) A genome-wide scan of serum lipid levels in the Old Order Amish. Atherosclerosis 173: 89–96.

39. Bell CG, Brenzina M, Siddiq A, Leocur C, Dina C, et al. (2004) Genome-wide linkage analysis for severe obesity in French Canadians finds significant susceptibility locus on chromosome 18p. Diabetes 53: 1057–1065.

40. Fritos MF, Racer T, North KE, Kraja A, Rankinen T, et al. (2005) PloS project QTL on chromosome 19q13 for triglycerides and adiposity: the HERITAGE family study. Atherosclerosis.

41. Weiss LA, Pan L, Abney M, Ober C (2006) The sex-specific genetic architecture of type 1 diabetes mellitus provisional report of a WHO consultation [see comments]. Diabet Med 15: 359–553.

42. Shephard RJ (2000) Exercise and training in women, Part I: Influence of gender on exercise and training responses. Can J Appl Physiol 25: 19–34.

43. Camper-Kirby D, Welch S, Walker A, Shiraishi I, Netchell KD, et al. (2001) Myocardial Akt activation and gender: increased nuclear activity in females versus males. Circ Res 88: 1020–1027.

44. Dupont W, Plummer Jr W. PS: Power and Sample Size Calculation.